13d ago
[Correspondence] Anti-β amyloid immunotherapy: not clinically meaningful
Francesco Nonino · Edo Richard
Abstract
We thank Nick C Fox and colleagues for their response1 to our study on the use of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.2 All amyloid β-targeting monoclonal antibodies, although binding to different epitopes of the β-amyloid protein, share the same objective: removing β-amyloid from the brain. Some antibodies other than lecanemab and donanemab also do so successfully, as established in several trials.3,4 Data from trials on agents sharing the same pathophysiological t
Discussion · 0
Sign in to join the discussion.